Analyst Price Targets — IEX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| October 19, 2026 11:22 am | — | Stifel Nicolaus | $267.00 | $235.55 | TheFly | Idex Corp. price target lowered to $267 from $268 at Stifel |
| September 9, 2026 11:37 am | — | Oppenheimer | $270.00 | $225.66 | TheFly | Idex Corp. price target raised to $270 from $265 at Oppenheimer |
| September 8, 2026 11:27 am | Jeffrey Sprague | Vertical Research | $250.00 | $223.74 | TheFly | Idex Corp. initiated with a Buy at Vertical Research |
| August 11, 2026 10:17 pm | Brett Linzey | Mizuho Securities | $280.00 | $237.31 | TheFly | Idex Corp. upgraded to Outperform from Neutral at Mizuho |
| August 6, 2026 1:15 pm | — | D.A. Davidson | $240.00 | $234.89 | TheFly | Idex Corp. price target raised to $240 from $230 at DA Davidson |
| July 30, 2026 12:09 pm | — | Oppenheimer | $265.00 | $236.82 | TheFly | Idex Corp. price target raised to $265 from $260 at Oppenheimer |
| July 30, 2026 11:21 am | Nathan Jones | Stifel Nicolaus | $268.00 | $229.52 | TheFly | Idex Corp. price target raised to $268 from $257 at Stifel |
| July 20, 2026 11:36 am | Nathan Jones | Stifel Nicolaus | $257.00 | $224.94 | TheFly | Idex Corp. price target raised to $257 from $250 at Stifel |
| July 16, 2026 12:17 pm | — | RBC Capital | $261.00 | $227.60 | TheFly | Idex Corp. price target raised to $261 from $252 at RBC Capital |
| June 2, 2026 11:32 am | — | Oppenheimer | $250.00 | $207.59 | TheFly | Idex Corp. price target raised to $250 from $242 at Oppenheimer |
Latest News for IEX
IEX heads into its Q3 2026 earnings report with expected revenue growth from Health & Science Technologies and acquisitions, but rising costs may pressure profits.
IDEX Corporation (IEX) continues to deliver robust revenue and profit growth across key segments, particularly Health & Science Technologies. Management raised 2026 organic revenue growth guidance to 5–6% and adjusted EPS to $8.70–$8.85, reflecting improved end-market demand. IEX's valuation remains elevated on both absolute and relative bases, limiting upside despite strong fundamentals and upgraded outlook.
Assenagon Asset Management S.A. cut its stake in shares of IDEX Corporation (NYSE: IEX) by 87.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,111 shares of the industrial products company's stock after selling 21,170 shares during
IDEX (NYSE: IEX - Get Free Report) and Blue Bird (NASDAQ: BLBD - Get Free Report) are both industrials companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends. Profitability This table compares IDEX and Blue Bird's net
Federal Signal (NYSE: FSS - Get Free Report) and IDEX (NYSE: IEX - Get Free Report) are both industrials companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings. Valuation and Earnings This table compares Federal Signal and
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.